Skip to main content
. Author manuscript; available in PMC: 2010 Aug 1.
Published in final edited form as: Mol Immunol. 2009 Jun 21;46(13):2655–2665. doi: 10.1016/j.molimm.2009.04.015

Figure 9. Inhibition of SFKs by PP2 partially overcomes BCR + CD19 signaling defect in B-1 cells.

Figure 9

(A) Transgenic splenic B cells were treated similar to that in Fig. 8B. Cells were pre-treated with different doses of PP2 (μM) and the calcium response to BCR + CD19 co-cross-linking shown on the gated splenic B-1 cells.

(B) 2.5 × 105 VH12 transgenic splenic B-1 cells (T-cell depleted) were cultured for 48 hours in an in vitro proliferation assay. Cells were incubated at 37°C with anti-IgM and different concentrations of the pharmacological inhibitor PP2. Shown is a representative graph from one of two independent experiments.